DOCSLIB.ORG

Calling Time the Nation’S Drinking As a Major Health Issue

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Calling Time the Nation’S Drinking As a Major Health Issue Calling Time The Nation’s drinking as a major health issue 12 250 10 200 8 150 6 100 4 50 to income Price relative 2 Litres of alcohol per person aged 15+Litres 0 0 1960 1964 1968 1970 1976 1980 1984 1988 1992 1996 2000 A report from the Academy of Medical Sciences With support from March 2004 The independent Academy of Medical Sciences promotes advances in medical science and public health and campaigns to ensure these are translated as quickly as possible into benefits for society. The Academy’s 750 Fellows are the United Kingdom’s leading medical scientists from hospitals, academia, industry and the public service. The aims of the Academy are to: • give national and international leadership in the medical sciences; • promote the application of research to the practice of medicine and to the advancement of human health and welfare; • promote the aims and ethos of medical sciences with particular emphasis on excellence in research and training; • enhance public understanding of the medical sciences and their impact on society; • assess and advise on issues of medical science of public concern. The Academy of Medical Sciences was established in 1998 following the recommendations of a working group chaired by Sir Michael Atiyah, Past President of the Royal Society. There is an elected Council of 22 Fellows that includes the five Officers of the Academy: President Sir Keith Peters, FRS, PMedSci Vice-President (Clinical) Lord Turnberg, FMedSci Vice-President (Non-clinical) Sir John Skehel, FRS, FMedSci Treasurer Sir Colin Dollery, FMedSci Registrar Professor Patrick Vallance, FMedSci The Academy is a registered charity and a company limited by guarantee. The Executive Director is Mrs Mary Manning. For more information about the work of the Academy please see www.acmedsci.ac.uk Registered Charity No.: 1070618 Registered Company No.: 3520281 Registered in England ISBN No.: 1-903401-06-2 Designed and produced by Quattro 020 7766 5225 Calling Time: The Nation’s drinking as a major health issure A report from the Academy of Medical Sciences March 2004 Acknowledgements The Academy of Medical Sciences is most grateful to Sir Michael Marmot and the members of the Working Group for conducting this inquiry. It would also like to thank the Review Group and the Academy’s Officers for their instructive comments and support. The Academy is grateful to the Society for the Study of Addiction for their financial support. Disclaimer This Report is published by the Academy of Medical Sciences and has been endorsed by its Officers and Council. Contributions by the Working Group are made purely in an advisory capacity. The Review Group added a further ‘peer-review’ stage of quality control to the process of Report production. The members of the Working Group and Review Group participated in this Report in an individual capacity and not as representatives of, or on behalf of, their individual affiliated hospitals, universities, organisations or associations (where indicated in the Cover image: Consumption of alcohol in the UK appendices). Their participation should not be taken (per person aged 15+) relative to its price 1960-2002 as an endorsement by these bodies. (Tighe, 2003) 4 Calling Time Contents Page Summary 7 Recommendations 9 Chapter one - Introduction 11 Chapter two - Do changes in population level drinking lead to changes in alcohol-related harm? 19 Review of the new evidence Chapter three - Reducing the harm from drinking 25 Chapter four - Conclusions and recommendations 33 Appendix one - References 37 Appendix two - Working and Review Group members 43 Appendix three- Terms of reference 45 Appendix four - Acronyms and abbreviations 45 5 Calling Time Figures and tables Figure 1 - Alcohol consumption in the UK: 1900-2000. Per capita consumption of 100% alcohol Figure 2 - Rising trend in deaths from chronic liver disease: 1970-2000 Figure 3 - Changing death rates from cirrhosis in England and the EU: 1970-1998 Figure 4 - Age-specific alcohol-related death rates in England and Wales: 1991-2000 Figure 5 - Consumption of alcohol in the UK (per person aged 15+) relative to its price: 1960-2002 Figure 6 - UK advertising expenditure at current prices and correlations with alcohol consumption in 11-15 year old children: 1992-2000 Figure 7 - Relationship between mean alcohol consumption and prevalence of drinking more than 28 units (approx 224g) of alcohol per week: men Table 1 - Number of deaths from chronic liver disease, England Table 2 - Abstinence rates in the UK and population alcohol consumption 6 Calling Time Summary Alcohol is an accepted part of our society, enjoyed by consumption of alcohol has risen by 50% in the the majority of the UK adult population and has health UK since 1970, whereas in France and Italy it has benefits, particularly in the area of Coronary Heart more than halved. Disease (CHD). The Academy has selected this focus in the knowledge However, there is clear evidence of an increasing that tackling general alcohol consumption is politically burden of harm from alcohol misuse: the Government contentious and an area in which it is difficult for has recognised this in asking the Prime Minister’s governments to intervene. But this is where there is Strategy Unit (PMSU) to develop a national alcohol evidence of opportunities to reduce harm, as part of harm reduction strategy, and the Academy of Medical a wider strategy. Sciences welcomes this. Compelling recent evidence supports previous findings In their Interim Report, the PMSU estimated that of a strong correlation between mean or median alcohol consumption in the United Kingdom is alcohol consumption and heavy or ‘problem’ drinking. responsible for a range of medical and social These cross-sectional data are supported by time-series consequences: analyses that demonstrate changes in per capita consumption are directly reflected in changes in harm. annual alcohol-related costs of crime and public • For instance, in Canada a one litre per annum rise in disorder £7.3 billion, workplace costs £6.4 billion, mean alcohol consumption was associated with a 30% and health costs £1.7 billion; increase in alcoholic cirrhosis of the liver. • 150,000 hospital admissions each year; • up to one-third of all accident and emergency Any benefit of a reduced population consumption attendances; of alcohol on deaths from cirrhosis or other alcohol- • about 2.9 million, or 7%, of the adult population related diseases has to be offset against the potential dependent on alcohol; loss of beneficial effects of alcohol on CHD. While • seven out of ten respondents to a poll saw drinking there may be beneficial effects of moderate drinking in public places as a problem in their locality; in the individual, this may outweigh health risks only • 47% of victims of violence believed that their in older people. At a population level, and at the assailant was under the influence of alcohol; per capita consumption found in the UK, it is unlikely • between 1993 and 2001 the total number of that overall reductions in consumption would have an casualties from road accidents involving alcohol adverse effect on deaths or morbidity from CHD. rose by one-fifth; Strategies to reduce alcohol consumption may be • between 30% and 60% of child protection cases general or targeted in their approach, but both tend involve alcohol. Up to 1.3 million children may be to have more impact on heavier, at-risk drinkers. adversely affected by family drinking. Educational approaches have been disappointing, but It is not the Academy’s intention to duplicate this work this may have been swamped by contrary advertising. and it expects the PMSU’s strategy to provide an Price modulation, usually through tax increases, is integrated and multifaceted approach. Specific highly effective, particularly in under-age drinkers; a high-risk groups, such as adolescent binge drinkers, 10% rise in price of all alcoholic beverages has been and certain high-risk situations, such as drink-driving estimated to reduce mortality from alcohol-related and drinking in public areas, are likely to be targeted. conditions by between 7 and 37%. The focus of this Report is the overall national The large ‘personal’ allowances for alcohol imported consumption of alcohol, the evidence that this is a from the European Union are disproportionately major determinant of harm and the opportunities generous compared to cigarettes and would act against for effective public health intervention that follow any benefits from price rises. The ‘personal’ allowance from this. It cannot be ignored that the per capita equates to a two year supply for a male drinking at 7 Calling Time the maximum ‘sensible’ level, compared to a 40 day the burden of alcohol-related harm in the population. supply for a 20-cigarette-per-day habit. Policy measures to address this harm are likely to cut across government departments. It also takes us outside Other crucial areas where alcohol consumption might the normal range of concern of a body such as be influenced include: the number and types of retail the Academy of Medical Sciences, but a broad outlets for alcohol, the hours they are open, random reach is necessary to build an effective strategy breath testing and the control of the drinking to reduce alcohol related problems. The scientific environment, particularly at night in Britain’s inner evidence indicates that, for the health of the cities. public, action is required to reduce the Therefore, the Academy concludes that there is much consumption of alcohol at a population level. evidence to link per capita alcohol consumption with 8 Calling Time Recommendations Recommendation one: Recommendation two: The balance of harm and benefit to society is There must be an extensive debate, involving all influenced by the total amount of alcohol consumed. sectors of the population, about alcohol-related harm Per capita alcohol consumption should be a pillar and the policies that might reduce it.
Load more

Recommended publications
  • Science & Policy Meeting Jennifer Lippincott-Schwartz Science in The
    SUMMER 2014 ISSUE 27 encounters page 9 Science in the desert EMBO | EMBL Anniversary Science & Policy Meeting pageS 2 – 3 ANNIVERSARY TH page 8 Interview Jennifer E M B O 50 Lippincott-Schwartz H ©NI Membership expansion EMBO News New funding for senior postdoctoral In perspective Georgina Ferry’s enlarges its membership into evolution, researchers. EMBO Advanced Fellowships book tells the story of the growth and ecology and neurosciences on the offer an additional two years of financial expansion of EMBO since 1964. occasion of its 50th anniversary. support to former and current EMBO Fellows. PAGES 4 – 6 PAGE 11 PAGES 16 www.embo.org HIGHLIGHTS FROM THE EMBO|EMBL ANNIVERSARY SCIENCE AND POLICY MEETING transmissible cancer: the Tasmanian devil facial Science meets policy and politics tumour disease and the canine transmissible venereal tumour. After a ceremony to unveil the 2014 marks the 50th anniversary of EMBO, the 45th anniversary of the ScienceTree (see box), an oak tree planted in soil European Molecular Biology Conference (EMBC), the organization of obtained from countries throughout the European member states who fund EMBO, and the 40th anniversary of the European Union to symbolize the importance of European integration, representatives from the govern- Molecular Biology Laboratory (EMBL). EMBO, EMBC, and EMBL recently ments of France, Luxembourg, Malta, Spain combined their efforts to put together a joint event at the EMBL Advanced and Switzerland took part in a panel discussion Training Centre in Heidelberg, Germany, on 2 and 3 July 2014. The moderated by Marja Makarow, Vice President for Research of the Academy of Finland.
    [Show full text]
  • Delivering Novel Therapies in the 21St Century Conference Report Held on 24 – 25 October 2018
    Part of the conference series Breakthrough science and technologies Transforming our future Delivering novel therapies in the 21st century Conference report Held on 24 – 25 October 2018 Supported by AstraZeneca Delivering novel therapies in the 21st century – Conference report 1 Introduction On 24 – 25 October 2018, the Royal Society and the Academy of Medical Sciences hosted a conference on novel medical therapies. The scientific programme for this meeting was developed by Steve Rees (Vice-President Discovery Biology, AstraZeneca), Professor Molly Stevens FREng (Professor of Biomedical Materials and Regenerative Medicine and Research Director for Biomedical Material Science, Imperial College London), and Sir John Skehel FMedSci FRS (Vice-President and Biological Secretary, the Royal Society). Image: Conference attendees networking. Presentations and discussions outlined recent scientific organised through the Royal Society’s Science and Industry advances in therapeutic modalities and delivery, the programme which demonstrates our commitment to integrate infrastructure required to develop novel treatments, and the science and industry at the Society, promote science and its implications of these advances for policy and healthcare value, build relationships and foster translation. delivery. The conference brought together scientists, technologists and experts from across academia, industry, The Academy’s FORUM programme brings together the NHS and public health, to discuss current challenges in industry, academia and the NHS, and the charity, regulatory human medicine, what future medicines will look like and and wider healthcare sectors. It provides an independent how we can prepare for them. platform for leaders from across the life sciences sector to discuss scientific opportunities, technology trends, This conference, supported by AstraZeneca, forms part of a translational challenges and strategic choices in healthcare.
    [Show full text]
  • The Impact of NMR and MRI
    WELLCOME WITNESSES TO TWENTIETH CENTURY MEDICINE _____________________________________________________________________________ MAKING THE HUMAN BODY TRANSPARENT: THE IMPACT OF NUCLEAR MAGNETIC RESONANCE AND MAGNETIC RESONANCE IMAGING _________________________________________________ RESEARCH IN GENERAL PRACTICE __________________________________ DRUGS IN PSYCHIATRIC PRACTICE ______________________ THE MRC COMMON COLD UNIT ____________________________________ WITNESS SEMINAR TRANSCRIPTS EDITED BY: E M TANSEY D A CHRISTIE L A REYNOLDS Volume Two – September 1998 ©The Trustee of the Wellcome Trust, London, 1998 First published by the Wellcome Trust, 1998 Occasional Publication no. 6, 1998 The Wellcome Trust is a registered charity, no. 210183. ISBN 978 186983 539 1 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as : Tansey E M, Christie D A, Reynolds L A. (eds) (1998) Wellcome Witnesses to Twentieth Century Medicine, vol. 2. London: Wellcome Trust. Key Front cover photographs, L to R from the top: Professor Sir Godfrey Hounsfield, speaking (NMR) Professor Robert Steiner, Professor Sir Martin Wood, Professor Sir Rex Richards (NMR) Dr Alan Broadhurst, Dr David Healy (Psy) Dr James Lovelock, Mrs Betty Porterfield (CCU) Professor Alec Jenner (Psy) Professor David Hannay (GPs) Dr Donna Chaproniere (CCU) Professor Merton Sandler (Psy) Professor George Radda (NMR) Mr Keith (Tom) Thompson (CCU) Back cover photographs, L to R, from the top: Professor Hannah Steinberg, Professor
    [Show full text]
  • Staff Changes Emma Bennett Joined the Academy As Exhibits Regularly in the UK and Europe
    Council Election Nobel Prize Congratulations to the following Fellows who Dr Sydney Brenner were elected to serve as new members of FRS HonFMedSci was awarded The Council with effect from 21 November 2002. Nobel Prize in Physiology or Medicine for 2002 for his research into genetic regulation of organ development and Professor Carol Black programmed cell death. Though now based in California, President, The Royal College of Physicians and Professor of Sydney Brenner’s discoveries whilst working in Cambridge, Rheumatology, Royal Free and University College Medical School UK, laid the foundation for this year’s prize which was awarded jointly to H Robert Horvitz and John E Sulston. Professor Nancy Rothwell MRC Research Professor, University of Manchester Professor Julia Goodfellow Chief Executive, the Biotechnology and Biological Sciences Research Council Professor Colin Bird Sir Douglas Black Formerly Dean of Medicine and Provost of Faculty Group of Medical and Veterinary Medicine, University of Edinburgh Sir Douglas Black: died September 13, 2002. It is with Medical School much sadness that we record the passing of a distinguished Honorary Fellow. The Black report was widely Professor Jonathan Cohen regarded as the most authoritative publication on the link Dean, Brighton & Sussex Medical School between poor health and social deprivation. That it became Professor Thomas Kirkwood so influential was at least in part due to the then Professor of Medicine, University of Newcastle Upon Tyne Government’s efforts to suppress its publication. Council is pleased to announce the appointment of Sir John Skehel, Sir Douglas was a widely respected and much loved FRS FMedSci, as Shadow Vice-President with responsibility for Professor of Medicine at Manchester and later President of non-clinical affairs.
    [Show full text]
  • Cambridge University Reporter Special Number 3
    SPECIAL NO. 3] OFFICERS NUMBER–MICHAELMAS TERM 2000 45 PA RT I I MEMBERS OF UNIVERSITY BODIES NOMINATING AND APPOINTING BODIES: ABBREVIATIONS C University Council CSHSS Council of the School of CST Council of the School of CSAH Council of the School of Humanities and Social Technology Arts and Humanities Sciences FC Finance Committee of the CSBS Council of the School of CSPS Council of the School of Council the Biological Sciences the Physical Sciences GB General Board of the Faculties Faculty Boards etc., as follows: AA Archaeology and ESG Earth Sciences and Mus Music Anthropology Geography OS Oriental Studies AHA Architecture and History HPS History and Philosophy of PC Physics and Chemistry of Art Science, Board of Phil Philosophy Biol Biology Hst History SPS Social and Political Cl Classics Law Law Sciences Div Divinity Math Mathematics Vet Clinical Veterinary Educ Education Med Clinical Medicine Medicine Engg Engineering MML Modern and Medieval X Co-opted, or appointed Engl English Languages by the body concerned EP Economics and Politics SEPTEMVIRI Prof. A. W.Cuthbert, F, Prof. P. Goddard, JN, Lady Perry, LC, ; Prof. J. H. Baker, CTH,(Chairman) , Dr C. H. Kelsey, G, Prof. Dame Gillian Beer, CLH, Prof. W.A. Brown, DAR, . COURT OF DISCIPLINE To Dec. Panel (a) Panel (b) Panel (c) Prof. W.R. Cornish, M Dr Y.M. Cripps, EM Ms H. E. Bromley, G Lord Goodhart, T, Chairman Dr J. C. D. Hickson, PEM Mr L. J. Burnett, F Mr A. D. Lemons, HH Ms U. Clifford, CL Dr R. C. Love, R Mr B. P.Corlett, JN Dr G.
    [Show full text]
  • BIOLOGY 639 SCIENCE ONLINE the Unexpected Brains Behind Blood Vessel Growth 641 THIS WEEK in SCIENCE 668 U.K
    4 February 2005 Vol. 307 No. 5710 Pages 629–796 $10 07%.'+%#%+& 2416'+0(70%6+10 37#06+6#6+8' 51(69#4' #/2.+(+%#6+10 %'..$+1.1); %.10+0) /+%41#44#;5 #0#.;5+5 #0#.;5+5 2%4 51.76+105 Finish first with a superior species. 50% faster real-time results with FullVelocity™ QPCR Kits! Our FullVelocity™ master mixes use a novel enzyme species to deliver Superior Performance vs. Taq -Based Reagents FullVelocity™ Taq -Based real-time results faster than conventional reagents. With a simple change Reagent Kits Reagent Kits Enzyme species High-speed Thermus to the thermal profile on your existing real-time PCR system, the archaeal Fast time to results FullVelocity technology provides you high-speed amplification without Enzyme thermostability dUTP incorporation requiring any special equipment or re-optimization. SYBR® Green tolerance Price per reaction $$$ • Fast, economical • Efficient, specific and • Probe and SYBR® results sensitive Green chemistries Need More Information? Give Us A Call: Ask Us About These Great Products: Stratagene USA and Canada Stratagene Europe FullVelocity™ QPCR Master Mix* 600561 Order: (800) 424-5444 x3 Order: 00800-7000-7000 FullVelocity™ QRT-PCR Master Mix* 600562 Technical Services: (800) 894-1304 Technical Services: 00800-7400-7400 FullVelocity™ SYBR® Green QPCR Master Mix 600581 FullVelocity™ SYBR® Green QRT-PCR Master Mix 600582 Stratagene Japan K.K. *U.S. Patent Nos. 6,528,254, 6,548,250, and patents pending. Order: 03-5159-2060 Purchase of these products is accompanied by a license to use them in the Polymerase Chain Reaction (PCR) Technical Services: 03-5159-2070 process in conjunction with a thermal cycler whose use in the automated performance of the PCR process is YYYUVTCVCIGPGEQO covered by the up-front license fee, either by payment to Applied Biosystems or as purchased, i.e., an authorized thermal cycler.
    [Show full text]
  • Year in Review
    Year in review For the year ended 31 March 2017 Trustees2 Executive Director YEAR IN REVIEW The Trustees of the Society are the members Dr Julie Maxton of its Council, who are elected by and from Registered address the Fellowship. Council is chaired by the 6 – 9 Carlton House Terrace President of the Society. During 2016/17, London SW1Y 5AG the members of Council were as follows: royalsociety.org President Sir Venki Ramakrishnan Registered Charity Number 207043 Treasurer Professor Anthony Cheetham The Royal Society’s Trustees’ report and Physical Secretary financial statements for the year ended Professor Alexander Halliday 31 March 2017 can be found at: Foreign Secretary royalsociety.org/about-us/funding- Professor Richard Catlow** finances/financial-statements Sir Martyn Poliakoff* Biological Secretary Sir John Skehel Members of Council Professor Gillian Bates** Professor Jean Beggs** Professor Andrea Brand* Sir Keith Burnett Professor Eleanor Campbell** Professor Michael Cates* Professor George Efstathiou Professor Brian Foster Professor Russell Foster** Professor Uta Frith Professor Joanna Haigh Dame Wendy Hall* Dr Hermann Hauser Professor Angela McLean* Dame Georgina Mace* Dame Bridget Ogilvie** Dame Carol Robinson** Dame Nancy Rothwell* Professor Stephen Sparks Professor Ian Stewart Dame Janet Thornton Professor Cheryll Tickle Sir Richard Treisman Professor Simon White * Retired 30 November 2016 ** Appointed 30 November 2016 Cover image Dancing with stars by Imre Potyó, Hungary, capturing the courtship dance of the Danube mayfly (Ephoron virgo). YEAR IN REVIEW 3 Contents President’s foreword .................................. 4 Executive Director’s report .............................. 5 Year in review ...................................... 6 Promoting science and its benefits ...................... 7 Recognising excellence in science ......................21 Supporting outstanding science .....................
    [Show full text]
  • 5.6 News 573&574
    news Cash crisis Pet problem Deep thoughts Clean sweep US museums Could cats play a Commission sets out US to help replace threatened by leading role in the blueprint for US Russia’s nuclear economic downturn fight against SARS? ocean policy facilities p575 p576 p577 p578 Harmful potential of viral vectors fuels doubts over gene therapy Erika Check, Washington The troubled field of gene therapy was M. KAY dealt a fresh blow this week, after a study suggested that modified viruses used in some trials might cause health problems. The study, led by geneticist Mark Kay at Stanford University, California, examined a modified virus used in gene-therapy trials to treat haemophilia and cystic fibrosis. It revealed that the virus has the potential to cause the same problems that led to cancer in an unrelated gene-therapy trial last year. In gene therapy, doctors use a gutted virus as a ‘vector’ to transfer corrective genes into a patient’s cells. But if the vector stitches itself into a cell’s genes, it can cause the cell to mutate and become cancerous. This was demonstrated last year, when two children who had gene therapy for severe combined immunodeficiency disease (SCID) developed leukaemia (see Nature 419,545–546; 2002). Scientists are still trying to establish exactly why the SCID patients developed cancer, and will discuss the trial at this week’s Doctors at Stanford treat a haemophiliac in a gene-therapy trial — but how safe is the procedure? meeting of the American Society of Gene Therapy in Washington DC. But most agree which can be engineered to infect human cystic fibrosis trials integrates itself more that gene therapy was the cause.
    [Show full text]
  • Annual Report 2019 & Financial Statements Year Ended 31 March 2019 2 N Medical Research Foundation Annual Report 2019 Contents
    Annual Report 2019 & financial statements year ended 31 March 2019 2 n Medical Research Foundation Annual Report 2019 Contents Our vision 5 How we arose 6 A note from the MRC’s Executive Chair 7 Welcome 8 Our objectives and activities 10–13 Our achievements and performance 14–25 New research that we supported 26–29 Plans for future periods 30 Thank you to all our supporters and donors 31 Our finances in 2018/19 32–35 Our structure, governance and management 36–38 Independent auditor’s report 40–41 Statement of financial activities 42–43 Balance sheet 44 Statement of cash flows 45 Notes to the financial statements 46–70 Legal and administrative information 71 Medical Research Foundation Annual Report 2019 n 3 4 n Medical Research Foundation Annual Report 2019 Our vision Changing medicine today. Changing lives tomorrow. The Medical Research Foundation’s vision is to advance medical research, improve human health and change people’s lives. Many of the diseases and conditions that affect human health have been cured or overcome as a result of medical research. But there will always be more to do. Although significant resources are being spent around the world on developing exciting new treatments and therapies, there are areas of medical need that receive little or no support – and people’s lives that see no improvement. That is where we step in. As the charitable foundation of the Medical Research Council (MRC) we are inspired by the responsibility and independence that our donated income gives us. We are guided by the wealth of expertise available to us and are bold and ambitious in the science we choose to support.
    [Show full text]
  • A New Home for Science and Discovery
    THE FRANCIS CRICK INSTITUTE A NEW HOME FOR SCIENCE AND DISCOVERY Annual Review 2016/17 WHO WE ARE CONTENTS The Francis Crick Institute is a Introduction 2 biomedical discovery institute dedicated Progress against our strategy 4 to understanding the fundamental Research highlights 16 biology underlying health and disease. Highlights from the year 30 Its work is helping to understand Our year in numbers 44 why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections and neurodegenerative diseases. For more information www.crick.ac.uk Right cover image: Wellcome Images WHAT’S INSIDE? INTRODUCTION PROGRESS AGAINST OUR STRATEGY RESEARCH HIGHLIGHTS HIGHLIGHTS FROM THE YEAR OUR YEAR IN NUMBERS Focus on how Science Technology Platforms are changing the way 12 42 we work INSPIRING THE NEXT GENERATION Dedicated laboratory for schools opened OPENING CEREMONY 39 New building opened by The Queen 30 25 Genetic switch may control cancer cell immortality 26 2 www.crick.ac.uk 1 INTRODUCTION INTRODUCTION BY PAUL NURSE 2 The Francis Crick Institute Annual Review 2016/17 INTRODUCTION PROGRESS AGAINST OUR STRATEGY RESEARCH HIGHLIGHTS HIGHLIGHTS FROM THE YEAR OUR YEAR IN NUMBERS A BEGINNING Having most of our staff physically together for the first time does feel like the real beginning of what I hope will become a special place for science and discovery. Welcome to our Annual Review for 2016/17: An exciting programme of seminars and a year which saw the Francis Crick Institute – lectures has been established, contributing its research and its people – come together to a lively culture of scientific interaction within in the new laboratories at St Pancras, London.
    [Show full text]
  • Lb,1111 Ilil +~~Ï+I~~~+ 1111 1111 I111 1111 1111 1111 1111, IIN 4' ,, NINETEENTH REPORT
    IlII II III I II I I I I 1'21 I I I1I I I I q I I I I I I I I I4 I I I I I I I I I 5I I IIOlhs 1 THE acaaernfc London and Wick UK microforme limited Web: www.academicmirrofonns.com I i WELLCOME TRUST 1989f90 p ST;NT3T ~ ,; lb,1111 IlIl +~~ï+i~~~+ 1111 1111 I111 1111 1111 1111 1111, IIN 4' ,, NINETEENTH REPORT Further copies of this report are available from: The Wellcome Trust I Park Square West London NWl 4LJ Tel: 071-486 4902 First pnblished 1991 @ The Trustees of the Wellcome Trust 1991 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any or by any means electronic. mechanical, photocopying, recording or otherwise, without the prior permission of the Wellcome Trust. Printed by Taylor Bloxham Limited, Leicester ISBN 1 869835 11 5 BOARD OF TRUSTEES CONTENTS Chairman R G Gibbs BOARD OF TRUSTEES 2 4 Deputy Chairman C E Gordon Smith, CB,MD,FRCP,FRCPath CHAIRMAN’S PREFACE INTRODUCTIONAND POUCY 5 Trustees The Rt Hon the Lord Swann, FRS (to February 1990) FINANCE Il Professor Sir Stanley Peart, MD, FRCP, FRS I Helm Muir, CBE, MA, DPhil, DSc, FRS ADMINISTRATION 13 (to September 1990) supporn FOR MEDICAL RESEARCH 20 J J B Jack, BM, PhD Sir Peter Cazalet CAREER DEVELOPMENT !%HEMES 24 Professor Sir David Weatherall, MD, FRCP, FRS PRINCIPAL RESEARCH FELLOWSHIPS AND SENIOR LEcTuRESHlpI 25 (from March 1990) SENlDR RESEARCH FELLOWSHIPS IN BASK BIOMEDIEU SCIENCES 27 Professor Sir Hans Kornberg, ScD, HonFRCP, FRS SENIOR RESEARCH FELLDWSHIPS 113 CLINICAL SCIENCE 29 (from October 1990) RESEARCH TRAININ<( FE-HIPS IN CUNKAL EPIDEM~OLOOY 31 Secretary to RESEARCH TRAINING FELLomHlps FOR MEDICALAND DENTAL oRu>umr 32 the Trustees P O Williams, DSc(Hon), DM(Hon).
    [Show full text]
  • Evolution of the SARS-Cov-2 Spike Protein in the Human Host
    Evolution of the SARS-CoV-2 spike protein in the human host Antoni Wrobel ( [email protected] ) The Francis Crick Institute https://orcid.org/0000-0002-6680-5587 Donald Benton Francis Crick Institute https://orcid.org/0000-0001-6748-9339 Chloë Roustan The Francis Crick Institute Annabel Borg The Francis Crick Institute Saira Hussain The Francis Crick Institute Stephen Martin Structural Biology Science Technology Platform, the Francis Crick Institute, Mill Hill Laboratory, London, UK. Peter Rosenthal The Francis Crick Institute https://orcid.org/0000-0002-0387-2862 John Skehel Francis Crick Institute Steve Gamblin The Francis Crick Institute https://orcid.org/0000-0001-5331-639X Biological Sciences - Article Keywords: SARS-CoV-2, virology, microbiology Posted Date: May 21st, 2021 DOI: https://doi.org/10.21203/rs.3.rs-535704/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Evolution of the SARS-CoV-2 spike protein in the human host Antoni Wrobel ( [email protected] ) The Francis Crick Institute https://orcid.org/0000-0002-6680-5587 Donald Benton Francis Crick Institute https://orcid.org/0000-0001-6748-9339 Chloë Roustan The Francis Crick Institute Annabel Borg The Francis Crick Institute Saira Hussain The Francis Crick Institute Stephen Martin Structural Biology Science Technology Platform, the Francis Crick Institute, Mill Hill Laboratory, London, UK. Peter Rosenthal The Francis Crick Institute https://orcid.org/0000-0002-0387-2862 John Skehel Francis Crick Institute Steve Gamblin The Francis Crick Institute https://orcid.org/0000-0001-5331-639X Biological Sciences - Article Keywords: SARS-CoV-2, virology, microbiology DOI: https://doi.org/10.21203/rs.3.rs-535704/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License.
    [Show full text]